Ma I-Hsin, Lai Tso-Ting, Yang Chang-Hao, Ho Tzyy-Chang, Yang Chung-May, Hsieh Yi-Ting
Department of Ophthalmology, National Taiwan University Hospital, Taipei 100225, Taiwan.
Department of Ophthalmology, National Taiwan University Hospital Hsin-Chu Branch, Biomedical Park Hospital, Hsinchu 302058, Taiwan.
J Pers Med. 2024 May 27;14(6):574. doi: 10.3390/jpm14060574.
To investigate the associations between fluid accumulation at different levels in the retina and visual outcome in polypoidal choroidal vasculopathy (PCV). A retrospective observational study. Institutional setting. A total of 91 eyes from 91 patients of PCV were included, with 65 receiving intravitreal aflibercept monotherapy and 26 receiving combined intravitreal ranibizumab and photodynamic therapy (PDT). Observation Procedures: Best-corrected visual acuity (BCVA) and optical coherence tomography (OCT) examination results were recorded at baseline and 3, 6, and 12 months after treatment. The correlations between visual outcomes and fluid biomarkers including intraretinal fluid (IRF), subretinal fluid (SRF), serous pigment epithelium detachment (PED), and hemorrhage at fovea were analyzed. No differences in treatment outcomes were noted between patients receiving aflibercept and those receiving combined ranibizumab and PDT. IRF and hemorrhage at baseline predicted poorer vision at 3, 6, and 12 months. The presence of IRF was associated with poorer vision at 6 months and 12 months ( < 0.05 for all). The presence of SRF or PED was not associated with better vision at any time point. No differences in the correlations between fluid markers and visual outcomes were noted between thin and thick subfoveal choroidal thickness groups. For PCV, IRF and hemorrhage at baseline served as surrogates for poor visual prognosis after treatment, and IRF was a biomarker for poor vision during the treatment course. No fluid markers predicted good visual prognosis or had a positive impact on vision at any time point.
探讨息肉状脉络膜血管病变（PCV）患者视网膜不同层面积液与视觉预后之间的关联。一项回顾性观察研究。机构环境。共纳入91例PCV患者的91只眼，其中65只眼接受玻璃体腔注射阿柏西普单药治疗，26只眼接受玻璃体腔注射雷珠单抗联合光动力疗法（PDT）。观察程序：记录基线时以及治疗后3、6和12个月的最佳矫正视力（BCVA）和光学相干断层扫描（OCT）检查结果。分析视觉预后与包括视网膜内液（IRF）、视网膜下液（SRF）、浆液性色素上皮脱离（PED）以及黄斑区出血在内的液体生物标志物之间的相关性。接受阿柏西普治疗的患者与接受雷珠单抗联合PDT治疗的患者在治疗结果上未发现差异。基线时的IRF和出血预示着3、6和12个月时视力较差。IRF的存在与6个月和12个月时视力较差相关（均P<0.05）。SRF或PED的存在在任何时间点均与较好视力无关。在黄斑下脉络膜厚度薄组和厚组之间，未发现液体标志物与视觉预后之间的相关性存在差异。对于PCV，基线时的IRF和出血可作为治疗后视力预后不良的替代指标，而IRF是治疗过程中视力不良的生物标志物。没有液体标志物能预测良好的视觉预后或在任何时间点对视力有积极影响。
